A SU011248 Expanded Access Protocol for Metastatic RCC Patients Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 04 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2011 Planned patient number is 350 according to ClinicalTrials.gov.
- 12 Dec 2011 Primary endpoint identified as 'Objective clinical response rate' as reported by ClinicalTrials.gov.